It has been demonstrated that in ascites fluid samples of ovarian cancer patients, especially in postchemotherapy samples, the majority of tumor cells are CD45+/EpCAM+ cells derived from the EpCAM+ primary tumor site. This evidence concerns the gene PTPRC and ovarian carcinoma.